Pablo M. Tebas
Expertise in
11
conditions

Dr. Pablo M. Tebas

Infectious Disease
University Of Penn-Medical Group
3400 Civic Ctr Blvd, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
34 Years of Experience
Expertise in
11
conditions
University Of Penn-Medical Group
3400 Civic Ctr Blvd, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Pablo Tebas is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Tebas has been practicing medicine for over 34 years is highly rated in 11 conditions, according to our data. His top areas of expertise are HIV/AIDS, Nontuberculous Mycobacterial Lung Disease, Swimming Pool Granuloma, and Sepsis.

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Infectious Disease
Licenses
Internal Medicine in PA
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF PENN-MEDICAL GROUP
3400 Civic Ctr Blvd, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses
Enrollment Status: Recruiting
Publish Date: September 23, 2024
Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Phase: Phase 3
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2024
Intervention Type: Drug
Study Drug: Elvitegravir+Cobicistat+Emtricitabine+Tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Study Phase: Phase 2
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug, Device
Study Drug: INO-4800
Study Phase: Phase 2/Phase 3
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Enrollment Status: Completed
Publish Date: December 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)
Enrollment Status: Unknown
Publish Date: June 25, 2021
Intervention Type: Drug
Study Drugs: Pegylated Interferon alpha 2b (peg-IFN-?2b), 3BNC117 + 10-1074
Study Phase: Phase 1
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Enrollment Status: Completed
Publish Date: January 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Enrollment Status: Completed
Publish Date: April 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy
Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy
Enrollment Status: Unknown
Publish Date: April 05, 2018
Intervention Type: Drug
Study Drug: Peg-IFN-?2b
Study Phase: Phase 2
View 12 Less Clinical Trials

152 Total Publications

Future of bNAbs in HIV Treatment.
Future of bNAbs in HIV Treatment.
Journal: Current HIV/AIDS reports
Published: April 30, 2025
Similar Doctors
Emily A. Blumberg
Expertise in
16
conditions
Dr. Emily A. Blumberg
Infectious Disease | Transplant Surgery
Expertise in
16
conditions
Dr. Emily A. Blumberg
Infectious Disease | Transplant Surgery

University Of Penn-Medical Group

3400 Civic Ctr Blvd, 
Philadelphia, PA 
 (0.1 mi)
215-662-6932
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Emily Blumberg is an Infectious Disease specialist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Blumberg is highly rated in 16 conditions, according to our data. Her top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, HIV/AIDS, Kidney Transplant, and Liver Transplant.

Expertise in
4
conditions
Dr. Karam C. Mounzer
Infectious Disease
Expertise in
4
conditions
Dr. Karam C. Mounzer
Infectious Disease
1233 Locust Street, 500, 
Philadelphia, PA 
 (1.6 mi)
215-790-1788
Languages Spoken:
English
See accepted insurances

Karam Mounzer is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Mounzer is highly rated in 4 conditions, according to our data. His top areas of expertise are HIV/AIDS, AIDS Dementia Complex, AIDS Dysmorphic Syndrome, and Myelitis.

Expertise in
4
conditions
Dr. Ian D. Frank
Infectious Disease
Expertise in
4
conditions
Dr. Ian D. Frank
Infectious Disease

University Of Penn-Medical Group

3400 Civic Ctr Blvd, 
Philadelphia, PA 
 (0.1 mi)
215-662-6932
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ian Frank is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Frank is highly rated in 4 conditions, according to our data. His top areas of expertise are HIV/AIDS, Myelitis, AIDS Dementia Complex, AIDS Dysmorphic Syndrome, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tebas's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile